Mealey's (November 14, 2018, 1:07 PM EST) -- ALEXANDRIA, Va. — Contrary to assertions by a petitioner for inter partes review (IPR), a patented regimen for treatment of low-grade, non-Hodgkin’s lymphoma is not obvious, patent owner Biogen Inc. maintains...
Biogen Defends Patent In Response To Petition For Inter Partes Review
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login